Insider Trading Alert - IDCC, NHI And LH Traded By Insiders
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
Friday, Feb. 27, 2015, 94 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $312.37 to $25,006,808.00.
Highlighted Stocks Traded by Insiders:
InterDigital (IDCC) - FREE Research Report
Kritzmacher John A, who is Director at InterDigital, sold 2,000 shares at $52.56 on Feb. 27, 2015. Following this transaction, the Director owned 8,403 shares meaning that the stake was reduced by 19.23% with the 2,000-share transaction.
The shares most recently traded at $53.50, up $0.94, or 1.76% since the insider transaction. Historical insider transactions for InterDigital go as follows:
- 4-Week # shares sold: 2,991
- 12-Week # shares sold: 12,686
- 24-Week # shares sold: 14,686
The average volume for InterDigital has been 370,200 shares per day over the past 30 days. InterDigital has a market cap of $2.0 billion and is part of the technology sector and telecommunications industry. Shares are down 0.06% year-to-date as of the close of trading on Friday.
InterDigital, Inc. designs and develops technologies that enable and enhance wireless communications in the United States, Taiwan, Canada, Japan, Korea, Germany, Europe, China, and Asia. The stock currently has a dividend yield of 1.52%. The company has a P/E ratio of 20.1. Currently, there is 1 analyst who rates InterDigital a buy, no analysts rate it a sell, and 1 rates it a hold.
Exclusive Offer: Get the latest Stock Analysis on IDCC - FREE
rates InterDigital as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
from
now.
National Health Investors (NHI) - FREE Research Report
Mccabe Robert A Jr, who is Director at National Health Investors, bought 398 shares at $71.17 on Feb. 27, 2015. Following this transaction, the Director owned 7,390 shares meaning that the stake was boosted by 5.69% with the 398-share transaction.
The shares most recently traded at $72.38, up $1.21, or 1.67% since the insider transaction. Historical insider transactions for National Health Investors go as follows:
- 4-Week # shares bought: 205
- 12-Week # shares bought: 205
- 24-Week # shares bought: 205
The average volume for National Health Investors has been 264,900 shares per day over the past 30 days. National Health Investors has a market cap of $2.7 billion and is part of the financial sector and real estate industry. Shares are up 1.74% year-to-date as of the close of trading on Friday.
National Health Investors Inc. is a real estate investment trust. It invests in the real estate markets of United States. The firm invests in the health care properties primarily in the long-term care and senior housing industries. The stock currently has a dividend yield of 4.33%. The company has a P/E ratio of 23.4. Currently, there is 1 analyst who rates National Health Investors a buy, no analysts rate it a sell, and 4 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on NHI - FREE
rates National Health Investors as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
National Health Investors Ratings Report
from
now.
Laboratory Corp of America Hldgs (LH) - FREE Research Report
Herring Joseph L, who is CEO of Covance Drug Division at Laboratory Corp of America Hldgs, sold 36,876 shares at $121.64 on Feb. 27, 2015. Following this transaction, the CEO of Covance Drug Division owned 0 shares meaning that the stake was reduced by 100% with the 36,876-share transaction.
The shares most recently traded at $123.60, up $1.96, or 1.59% since the insider transaction. Historical insider transactions for Laboratory Corp of America Hldgs go as follows:
- 4-Week # shares sold: 2,714
- 12-Week # shares sold: 2,714
- 24-Week # shares sold: 2,714
The average volume for Laboratory Corp of America Hldgs has been 1.5 million shares per day over the past 30 days. Laboratory Corp of America Hldgs has a market cap of $10.5 billion and is part of the health care sector and health services industry. Shares are up 14.02% year-to-date as of the close of trading on Friday.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. The company has a P/E ratio of 21.1. Currently, there are 12 analysts who rate Laboratory Corp of America Hldgs a buy, no analysts rate it a sell, and 6 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on LH - FREE
rates Laboratory Corp of America Hldgs as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
Laboratory Corp of America Hldgs Ratings Report
from
now.
null